drugset / Trial / NCT05399641
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2023-05-16
- Completion
- 2023-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrexafungerp | Small molecule | 300 mg | Oral |